 |
|
|
|
|
|
|
|
 |
|
||||||
 |
 |
 |
 |
 |
 |
 |
|
Analyst Conference Summaries
Alexion Pharmaceuticals
ALXN
conference date: February 4, 2021 @ 5:00 AM Pacific Time
Alexion: A Good Buy For Long Term Appreciation [July 4, 2019 @ Seeking Alpha]
Alexion: Priced Right For Long-Term Investors [August 16, 2018 at Seeking Alpha]
I buy Alexion [February 3, 2015 at Dissecting the Bull]
Alexion's Rare Disease Model Analyzed [December 18, 2014 @ Seeking Alpha]
| 2021 | |||
| Alexion Q4 2020 |
To be acquired by AstraZeneca | ||
| Feb. 4, 2021 | |||
| 2020 | |||
| Alexion Q4 2019 |
Alexion Q1 2020 |
Alexion Q2 2020 |
Alexion Q3 2020 |
| Jan. 30, 2020 | May 6, 2020 | July 30, 2020 | Oct. 29, 2020 |
| 2019 | |||
| Alexion Q4 2018 |
Alexion Q1 2019 |
Alexion Q2 2019 |
Alexion Q3 2019 |
| Feb. 4, 2019 | April 25, 2019 | July 24, 2019 | Oct. 23, 2019 |
2018 |
|||
Feb. 8, 2018 |
April 12, 2018 |
July 26, 2018 |
Oct. 24, 2018 |
2017 |
|||
02/16/2017 |
04/27/2017 |
July 27, 2017 |
Oct. 26, 2017 |
2016 |
|||
02/03/2016 |
04/28/2016 |
07/28/2016 |
10/27/2016 |
2015 |
|||
01/29/2015 |
05/23/2015 |
07/30/2015 |
10/29/2015 |
2014 |
|||
01/30/2014 |
04/24/2014 |
07/24/2014 |
10/23/2014 |
2013 |
|||
07/25/2013 |
10/24/2013 |
||
Alexion Pharmaceuticals (ALXN) is a biotechnology company specializing in rare blood disorders.
Alexion web site
Alexion investor relations page
I owned Alexion between February 3, 2015 and May 18, 2017, took my losses, illustrating the danger in investing in a priced-over-perfection stock. Price was pretty reasonable when I sold it, but I had just had a major gain with GlycoMimetics, and decided to reduce my debt.
I reserve the right to buy or sell the stock at any time without notice. Investors are welcome to read my notes and opinions, which are journalism, not financial advice.
More Analyst Conference Pages:
| AGEN |
| ALNY |
| ALXN |
| AMAT |
| AMGN |
| APRE |
| ARWR |
| BIIB |
| BMY |
| CELG |
| DRNA |
| EPZM |
| GILD |
| GLYC |
| ILMN |
| INCY |
| INO |
| IONS |
| ISRG |
| MCHP |
| MRNA |
| REGN |
| RNA |
| SGEN |
| TTPH |
| VBLT |
| VSTM |
| XLRN |
Disclaimer: Our analyst summaries may include both our condensations of statements made by company representatives and our own analysis. They are not covered by any warranty. We cannot guarantee anything said by company representatives is true. We try not to make errors, but it is possible. Before making or terminating an investment you should always verify any factual basis of your decision.
Copyright 2020 William P. Meyers